Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | IL6 | P05231 | 1/20 | 0.63 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.63 |
| ▸ | GLUL | P15104 | 1/20 | 0.63 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone Metazoate SCHEMBL2916561 | 0.99 | PGR (0.70) | PGRHIF1ALMNANR3C1HSD17B10 | |
| Prednisolone Metazoate SCHEMBL29379658 | 0.92 | PGR (0.68) | PGRHIF1ALMNANR3C1HSD17B10 | |
| Prednisolone Metazoate SCHEMBL5013651 | 0.92 | PGR (0.68) | PGRHIF1ALMNANR3C1HSD17B10 | |
| Prednisolone Metazoate SCHEMBL2796992 | 0.92 | PGR (0.68) | PGRHIF1ALMNANR3C1HSD17B10 | |
| Prednisolone Metazoate SCHEMBL1042225 | 0.92 | PGR (0.68) | PGRHIF1ALMNANR3C1HSD17B10 | |
| Prednisolone Metazoate SCHEMBL5483013 | 0.92 | PGR (0.68) | PGRHIF1ALMNANR3C1HSD17B10 | |
| SCHEMBL27462874 | 0.89 | HIF1A (0.72) | PGRHIF1ALMNANR3C1HSD17B10 | |
| SCHEMBL28852123 | 0.88 | HIF1A (0.73) | PGRHIF1ALMNANR3C1HSD17B10 | |
| SCHEMBL9836047 | 0.87 | PGR (0.71) | PGRHIF1ALMNANR3C1HSD17B10 | |
| Prednisolone SCHEMBL4318103 | 0.87 | NR3C1 (0.71) | PGRHIF1ALMNANR3C1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| CN-114716544-A | Complement component C5 antibody | 阿勒根公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-107207585-B | Complement component C5 antibody | 阿勒根公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-106456751-B | Method for treating nail and scalp psoriasis | 安姆根K-A有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-110724691-A | Complement factor Bb antibodies | 阿勒根公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-106232624-B | Complement factor Bb antibodies | 阿勒根公司 | 2020-01-21 | — | — | CN | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| CN-1240479-A | Truncated soluble tumor necrosis factor type-I and type-II receptors | AMGEN INC (US) | 2000-01-05 | — | — | CN | disclosed |
| US-4296109-A | ANTISHOCK, ANTIINFLAMMATORY | SCHERING, AKTIENGESELLSCHAFT (DE) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | PGR 965/4885HIF1A 1076/4885LMNA 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.